51336-95-9

Basic information

• Product Name: 2-Chloro-1-(3,4-difluoro-phenyl)-ethanone
• Synonyms: 2-CHLORO-1-(3,4-DIFLUORO-PHENYL)-ETHANONE;2-Chloro-1-(3,4-difluorophenyl)ethan-1-one;3,4-Difluorophenacyl chloride;a-Chloro-3,4-difluoroacetophenone;Ethanone,2-chloro-1-(3,4-difluorophenyl)-;Fluconazole Impurity 6
• CAS NO: 51336-95-9
• Molecular Formula: C₈H₅ClF₂O
• Molecular Weight: 190.57
• EINECS: 1312995-182-4
• Product Categories: Methyl Halides;Phenyls & Phenyl-Het;Methyl Halides;Phenyls & Phenyl-Het;Acetophenone series
• Mol File: 51336-95-9.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 256.3 °C at 760 mmHg
• Flash Point: 108.8 °C
• Appearance: /
• Density: 1.353 g/cm³
• Vapor Pressure: 0.0155mmHg at 25°C
• Refractive Index: 1.495
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• Solubility: soluble in Methanol
• Sensitive: Lachrymatory
• CAS DataBase Reference: 2-Chloro-1-(3,4-difluoro-phenyl)-ethanone(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Chloro-1-(3,4-difluoro-phenyl)-ethanone(51336-95-9)
• EPA Substance Registry System: 2-Chloro-1-(3,4-difluoro-phenyl)-ethanone(51336-95-9)

Safety Data

• Hazard Codes: C,Xi
• RIDADR: UN 3261 8/PG II
• HazardClass: IRRITANT
• PackingGroup: II
• Hazardous Substances Data: 51336-95-9(Hazardous Substances Data)

Usage

InChI:InChI=1/C8H5ClF2O/c9-4-8(12)5-1-2-6(10)7(11)3-5/h1-3H,4H2

Upstream product

• 367-11-3 ortho-difluorobenzene 
• 79-04-9 chloroacetyl chloride 

Downstream Products

• 308368-70-9 [2-(4-{4-[4-(3,4-difluoro-phenyl)-thiazol-2-yl]-benzenesulfonylamino}-phenyl)-ethyl]-(2-hydroxy-2-pyridin-3-yl-ethyl)-carbamic acid tert-butyl ester 
• 1735-32-6 2-(3,4-difluorophenyl)benzopyrazine 
• 376608-71-8 trans-(1R,2S)-2-(3,4-difluorophenyl)cyclopropylamine (2R)-2-hydroxy-2-phenylacetic acid salt 
• 1006376-60-8 (1S)-2-chloro-1-(3,4-difluorophenyl)-1-ethanol 
• 1450916-28-5 (1R,2R)-2-(3,4-difluorophenyl)cyclopropane carbonitrile 
• 1415240-28-6 C₁₇H₁₇F₂NO₂ 
• 1415240-33-3 C₁₇H₁₇F₂NO 
• 339001-18-2 C₁₆H₁₅F₂NO 
• 1415240-26-4 C₁₇H₁₇F₂NO 
• 1395882-27-5 C₁₁H₉F₂N₃O 
• 351042-08-5 C₁₀H₇F₂N₃O 
• 1381841-39-9 2-((1S,2S,3S,4R)-4-(7-(((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)amino-5-propylthio-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-2,3-dihydroxycyclopentyl)oxy)ethyl butyrate 
• 1006376-62-0 (1R,2R)-trans-2(3,4-difluorophenyl)cyclopropyl carboxamide 
• 376608-70-7 trans-(1R,2R)-2-(3,4-difluorophenyl)cyclopropanecarbonyl chloride 

Relevant articles and documents

Stereoselective synthesis of the key intermediate of ticagrelor and its diverse analogs using a new alcohol dehydrogenase from Rhodococcus kyotonensis

Bioreduction catalyzed by alcohol dehydrogenase/reductase is one of the most valuable biotransformation processes widely used in industry. The (S)-2-Chloro-1-(3, 4-difluorophenyl) ethanol is a key chiral synthon for synthesizing the antithrombotic agent ticagrelor. Herein, a new alcohol dehydrogenase (named Rhky-ADH) identified from Rhodococcus kyotonensis by an enzyme promiscuity-based genome mining method was successfully cloned and functionally expressed in Escherichia coli. The whole cell biocatalyst harboring Rhky-ADH was biochemically characterized and was shown to be able to convert 2-Chloro-1-(3, 4-difluorophenyl) ethanone to (S)-2-Chloro-1-(3, 4-difluorophenyl) ethanol with more than 99 % enantiomeric excess (ee) and 99 % conversion. Our data showed that the optimum temperature and pH for Rhky-ADH were 25 °C and pH 8.0, respectively. The addition of NADH and an appropriate concentration of isopropanol enhanced the activity of Rhky-ADH, and 1 mM Mn2+ increased the enzyme activity by about 8 %. Substrate specificity experiments showed that Rhky-ADH had notable enzyme promiscuity and could reduce several ketones with high stereoselectivity. Our investigation on this novel enzyme adds another rare biocatalyst to the toolbox for producing chiral alcohols, which are widely used in the pharmaceutical industry.

Preparation method of ticagrelor

The invention discloses a preparation method of ticagrelor. The preparation method comprises the following steps: (1) preparation of ticagrelor intermediate product 1-TK acid; (2) preparation of ticagrelor intermediate product 2-TK-amide; (3) preparation of ticagrelor intermediate product 3-TK-amino compound hydrochloride; (4) preparation of ticagrelor intermediate product 4-TK-amino compound R-tartrate; ( 5) preparation of ticagrelor intermediate product 5-TK-amino compound L-mandelate; and (6) preparation of ticagrelor-TK. The preparation method has the advantages of cost advantage, mature and stable process, stable product quality, and safe and reliable production process.

(1 R, 2 S) - 2 - (3, 4 - difluorophenyl) amine ·D - mandelic acid salt preparation method

The invention discloses a preparation method of (1R,2S)-2-(3,4-difluorophenyl) rolicyprine.D-mandelate. The preparation method comprises the following steps: carrying out cyclopropanation on a compound shown in a formula V to obtain a compound shown in a formula IV; carrying out amide generation and Hofmann degradation to obtain a compound shown in a formula II; and performing salification with D-mandelic acid to obtain a compound shown in a formula I. The compound shown in the formula V is prepared in a way that a compound shown in a structure formula VI is subjected to CBS asymmetric reduction reaction, wherein a catalyst for the CBS asymmetric reduction reaction is a compound shown in a structural formula VII, and a reduction agent for the CBS asymmetric reduction reaction can be borane-tetrahydrofuran or borane-N,N-diethyl phenylamine.